240 related articles for article (PubMed ID: 31410218)
1. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas.
Penco-Campillo M; Molina C; Piris P; Soufi N; Carré M; Pagnuzzi-Boncompagni M; Picco V; Dufies M; Ronco C; Benhida R; Martial S; Pagès G
Cells; 2022 Dec; 11(23):. PubMed ID: 36497191
[TBL] [Abstract][Full Text] [Related]
3. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
4. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
[TBL] [Abstract][Full Text] [Related]
5. IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway.
Chan LP; Wang LF; Chiang FY; Lee KW; Kuo PL; Liang CH
Oncotarget; 2016 Sep; 7(38):61820-61831. PubMed ID: 27557518
[TBL] [Abstract][Full Text] [Related]
6. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
8. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
9. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.
Varney ML; Singh S; Li A; Mayer-Ezell R; Bond R; Singh RK
Cancer Lett; 2011 Jan; 300(2):180-8. PubMed ID: 21035946
[TBL] [Abstract][Full Text] [Related]
10. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
11. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
12. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
13. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
14. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.
Wang J; Hu W; Wang K; Yu J; Luo B; Luo G; Wang W; Wang H; Li J; Wen J
Int J Oncol; 2016 Apr; 48(4):1341-52. PubMed ID: 26847910
[TBL] [Abstract][Full Text] [Related]
15. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2.
Zaslaver A; Feniger-Barish R; Ben-Baruch A
J Immunol; 2001 Jan; 166(2):1272-84. PubMed ID: 11145710
[TBL] [Abstract][Full Text] [Related]
16. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.
Singh S; Wu S; Varney M; Singh AP; Singh RK
Microvasc Res; 2011 Nov; 82(3):318-25. PubMed ID: 21749879
[TBL] [Abstract][Full Text] [Related]
17. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
18. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
19. The ELR
Giuliano S; Guyot M; Grépin R; Pagès G
Oncoimmunology; 2014; 3():e28399. PubMed ID: 25050209
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
